OTHER GROUP COMPANIES
market

SMS Pharmaceuticals gets license to manufacture oral antiviral drug Molnupiravir

The Company has received a non-exclusive license through the Medicines Patent Pool (MPP) to manufacture Molnupiravir.

January 21, 2022 2:38 IST | India Infoline News Service
SMS Pharmaceuticals Limited has received a non-exclusive license through the Medicines Patent Pool (MPP) to manufacture Molnupiravir, an investigational oral antiviral Covid-19 medicine, to increase broad access of treatment in 105 low-and middle-income countries (LMIC).

MSD, a trade name of Merck & Co Inc, Kenilworth, NJ, USA has entered into an agreement to license this pill for wider distribution with patent group. Under the terms of the agreement, MPP, through the license granted by MSD, will be permitted to further license non-exclusive sublicenses to manufactures and diversify the manufacturing base for the supply of molnupiravir to countries covered by the MPP Licence, subject to local regulatory authorization.

At around 2:37 PM, SMS Pharmaceuticals was trading at Rs132.45 per share down by Rs4.3 or 3.14% on Sensex.

OPEN A DEMAT ACCOUNT & Get
FREE Benefits Worth 5,000

FEATURED ARTICLE

BLOGS

Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity